Clinical trial

Next Generation Sequencing Approach to the Study of Rheumatic Heart Disease

Name
2013P002682/BWH
Description
Rheumatic fever (RF) is an autoimmune disease that is mediated by the cellular and humoral immune response that follows an untreated pharyngeal Streptococcus pyogenes infection. The most serious complication is rheumatic heart disease (RHD), one of the most common problems facing children and young adults worldwide, which leads to chronic valvular lesions. It is estimated that 60% of all acute rheumatic fever cases will develop RHD. The pathogenesis of RHD is complex with both environmental and genetic factors contributing to its etiology. The investigators know little about the genetic etiology, cellular events and modifiers of progression of RHD, and there exists a wide range of disease severity and progression to severe valve pathology. Thus, the investigators will study the genetics of RHD in Rwanda, a country with a very high incidence of RHD, using a combination of next-generation targeted exome capture, transcriptomics, and expressed quantitative trait loci (eQTL) analysis.
Trial arms
Trial start
2014-02-01
Estimated PCD
2024-07-01
Trial end
2024-07-01
Status
Recruiting
Treatment
Next generation sequencing
There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
Arms:
NO rheumatic heart disease by echo, Rheumatic heart disease by echo
Size
1000
Primary endpoint
Echocardiographic signs of rheumatic heart disease
3 years
Eligibility criteria
Inclusion Criteria: * Clinical and echocardiographic signs of RHD using WHF criteria Exclusion Criteria: * Congenital heart disease
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '5 Years', 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'The investigators are collecting blood for DNA analysis from all subjects as well as heart valve tissue from subjects who undergo cardiac surgery.'}, 'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}}
Updated at
2023-02-08

1 organization

1 product

1 indication